Neuro-Oncology Reviews
Volume
27 Number 15
31 May 2025
Home > Publications > Neuro-Oncology Reviews > Volume 27, Year 2025 > Number 15, 31 May
Barańska K, Niemas K, Pełka K, Kunikowska J.
PET/CT
in the Imaging of CNS Tumors.
Semin
Nucl Med. 2025 May 21:S0001-2998(25)00040-6. doi:
10.1053/j.semnuclmed.2025.04.002. PMID:
40404539. Review˰ ˍ
Beylerli O, Gareev I, Kaprin A, Ahmad A, Chekhonin V, Yang S, Yang
G.
Hemorrhagic and ischemic risks of
anti-VEGF therapies in glioblastoma.
Cancer
Gene Ther. 2025 May 21. doi:
10.1038/s41417-025-00914-8. PMID:
40394233. Review˰ ˍ
Elliott WJ, Gurramkonda N, Guda MR, Tsung AJ, Velpula KK.
Survivin Interference and SurVaxM as
an Adjunct Therapy for Glioblastoma Multiforme.
Cells.
2025 May 21;14(10):755. doi:
10.3390/cells14100755. PMID:
40422257. Review. ˍ
Expert Panel on Neurological Imaging; Ivanidze J, Shih RY, Utukuri
PS, Ajam AA, Auron M, Chang SM, Jordan JT, Kalnins A, Kuo PH,
Ledbetter LN, Pannell JS, Pollock JM, Sheehan J, Soares BP,
Soderlund KA, Wang LL, Burns J.
ACR Appropriateness
Criteria® Brain Tumors.
J
Am Coll Radiol. 2025 May 21;22(5S):S108-S135. doi:
10.1016/j.jacr.2025.02.036. PMID:
40409872. Guidelines. ˍ
Sun Y, Wang Y, Mu S, Wu X, Yu S, Wang Z.
Combining
immunotherapy with radiotherapy for glioblastoma: recent advances
and challenges.
Front
Oncol. 2025 May 22;15:1523675. doi:
10.3389/fonc.2025.1523675. PMID:
40475019.
Review. ˍ
Williams A, Neth B, Webb M, Schwartz J, Daniels D, Caron S,
Campian J, Uhm J, Ida C, Breen WG, Raghunathan A, Sener U.
Diffuse hemispheric glioma, H3
G34-mutant: defining the clinical picture through a single
institution case series and literature analysis.
J
Neurooncol. 2025 May 22. doi:
10.1007/s11060-025-05028-7. PMID:
40402198. Case report; Review˰
ˍ
Zhang L, Tang G, Sun X, Xiao X, Ma F.
Assisted
reproductive technology and risk of malignancy among offspring: a
meta-analysis.
Int
J Surg. 2025 May 22. doi:
10.1097/JS9.0000000000002554. PMID:
40405863. Meta-analysis. ˍ
Fredricks N, Price A, Jonzzon S, D'Souza P, Wellons JC, Ramaswamy
V, Dewan MC.
Surgical management of
recurrent medulloblastoma: a scoping review.
J
Neurosurg Pediatr. 2025 May 23:1-7. doi:
10.3171/2025.2.PEDS2534. PMID:
40408881. Review˰ ˍ
Lee C, Lee J, Jeong M, Nam D, Rhee I.
Emerging
strategies for targeting tumor-associated macrophages in
glioblastoma: A focus on chemotaxis blockade.
Life
Sci. 2025 May 24;376:123762. doi:
10.1016/j.lfs.2025.123762. PMID:
40419107. Review˰ ˍ
Chen
Y, Ding K, Zheng S, Gao S, Xu X, Wu H, Zhou F, Wang Y, Xu J, Wang
C, Ling C, Xu J, Wang L, Wu Q, Giamas G, Chen G, Zhang J, Yi C, Ji
J.
Post-translational
modifications in DNA damage repair: mechanisms underlying
temozolomide resistance in glioblastoma.
Oncogene.
2025 May 26;44(23):1781-1792. doi:
10.1038/s41388-025-03454-5. PMID:
40419791. Review. ˍ
Shankar V, Harshil Sai V, Cholayil S.
Letter
to the Editor Regarding "Metformin as an Adjunct Treatment to
Temozolomide for High-Grade Gliomas: A Systematic Review and
Meta-Analysis".
World
Neurosurg. 2025 May 26;199:124121. doi:
10.1016/j.wneu.2025.124121. PMID:
40436336. Letter. ˍ
RELATED
ARTICLE
Bittencurt
Thomaz de Assis E, Ferreira MY, Sales de Oliveira J, Mitre LP,
Correa da Silva EM, Salim Coelho LL, Moreno DA, Polverini AD.
Metformin
as an Adjunct Treatment to Temozolomide for High-Grade Gliomas: A
Systematic Review and Meta-Analysis.
World
Neurosurg.
2025 Feb 27;197:123842. doi:
10.1016/j.wneu.2025.123842. PMID:
40023279. Review; Meta-Analysis.
ˍ
Wu
W, Xie Y, Jiang C, Jiang X.
Unveiling
the multifaceted functions of TRIM proteins in glioma
pathogenesis.
Transl
Oncol.
2025 May 26;58:102419. doi:
10.1016/j.tranon.2025.102419. PMID:
40424933. Review. ˍ
Mojica CV, Gutierrez KME, Mason WP.
Advances
in IDH-mutant glioma management: IDH inhibitors, clinical
implications of INDIGO trial, and future perspectives.
Future
Oncol. 2025 May 27:1-11. doi:
10.1080/14796694.2025.2511587. PMID:
40424199. Review˰ ˍ
Stański M, Wątorek J, Antczak S, Ciesielski M, Katulska
B, Goralewski M, Moskal J, Katulska K.
Brain
MRI morphometry for structural alterations in patients with glioma
- A systematic review.
Eur
J Radiol Open. 2025 May 27;14:100660. doi:
10.1016/j.ejro.2025.100660. PMID:
40502299.
Review. ˍ
Mahboubi E, Mondanizadeh M, Almasi-Hashiani A, Ghasemi E.
Exploring the effects of doxorubicin
on survival rates in glioma patients: a comprehensive systematic
review.
Eur
J Med Res. 2025 May 28;30(1):425. doi:
10.1186/s40001-025-02674-5. PMID:
40437615. Review. ˍ
Aghedi M, Larijani A, Bagheri AB, Rafiemanesh H, Saraee E, Mardi
S, Shirani M.
Efficacy of combined
therapy with gamma knife radiosurgery and bevacizumab on survival
outcomes in patients with recurrent high-grade glioma: a
systematic review and meta-analysis.
Neurosurg
Rev. 2025 May 29;48(1):459. doi:
10.1007/s10143-025-03632-9. PMID:
40439764.
Review;
Meta-Analysis.
ˍ
Kusaczuk M, Piskorz WM, Domasik J.
Marizomib
in the therapy of brain tumors-how far did we go and where do we
stand?
Pharmacol
Rep. 2025 May 29. doi:
10.1007/s43440-025-00739-0. PMID:
40439869. Review. ˍ
Baptista
JM, Brenner LBO, Henrique A, Ito LA, Nabarro PH, Santos LP,
Palavani LB, Berbet LU, Koga JV, Salvarani CP, Nespoli VS, Bertani
R.
Efficacy
and safety of intraoperative magnetic resonance imaging for
low-grade and high-grade gliomas: an updated systematic review and
meta-analysis.
Neurosurg
Rev.
2025 May 30;48(1):465. doi:
10.1007/s10143-025-03631-w. PMID:
40445417.
Review;
Meta-Analysis˰
ˍ
Tomaselli A, Luca A, Ferini G, Umana GE, Chaurasia B, Scalia G.
Cognitive Profiles and Determinants of
Eligibility for Awake Surgery in Non-Dominant Hemisphere Gliomas:
A Narrative Review.
Brain
Behav. 2025 May 30;15(6):e70604. doi:
10.1002/brb3.70604. PMID:
40444665. Review. ˍ
Wang M, Wang Z, Zhang G, Fan J.
Interleukin-enhanced
CAR-engineered immune cells in tumor immunotherapy: current
insights and future perspectives.
Cytokine.
2025 May 30;192:156973. doi:
10.1016/j.cyto.2025.156973. PMID:
40449036. Review˰ ˍ
Xuan F, Lv T, Zheng L, Yu S, Ding M.
Analysis
of the correlation between inflammatory cytokines and
glioblastoma: A Mendelian randomization study.
Medicine
(Baltimore). 2025 May 30;104(22):e42137. doi:
10.1097/MD.0000000000042137. PMID:
40441232. Meta-Analysis.
ˍ
Bao J, Pan Z, Wei S.
Unlocking new
horizons: advances in treating IDH-mutant, 1p/19q-codeleted
oligodendrogliomas.
Discov
Oncol. 2025 May 31;16(1):971. doi:
10.1007/s12672-025-02815-6. PMID:
40448901. Review. ˍ
Karbhari N, Frechette KM, Burns TC, Parney IF, Campian JL, Breen
WG, Sener UT, Lehrer EJ.
Immunotherapy
for High-Grade Gliomas.
Cancers
(Basel). 2025 May 31;17(11):1849. doi:
10.3390/cancers17111849. PMID:
40507329. Review. ˍ